arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Cardio Diagnostics Holdings, Inc.

CDIO
$1.92 ▼ -0.01 (-0.52%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
22 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cardio Diagnostics Holdings, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $5.7M
Dividend Yield
Revenue Growth -28.3%
Op. Margin
ROIC -15.9%
FCF / Share $-0.45
Trailing P/E
Price / Book 0.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

22-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$5.36K
↓ -28.3%
Net Income Profit after all expenses
$-1.50M
↑ +10.8%
FCF / Share Free cash flow per share
$-0.45
↑ +17.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
10
Financial Health
7
Cash Quality
61

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 22 quarters